Business Wire

ARTHUR-D.-LITTLE

15.3.2022 10:02:08 CET | Business Wire | Press release

Share
Arthur D. Little Promotes Nine New Partners Across Global Offices

Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005634/en/

Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and clients they serve, and best-in-class experience and expertise. ADL credits a lot of its ongoing growth and success to the development, promotion and retention of its internal talent, with a recent survey on Vault acknowledging these values for setting ADL apart as an employer.

The latest promotions to Partner are as follows:

  • Ryan Alnesayan, Partner, Public Services Practice, Riyadh. Leading ADL Riyadh’s office, Ryan has over 14 years of consulting and business advisory experience in strategic planning, economic development, and large-scale transformation projects, with a focus on Saudi Arabia.
  • Marcus Beard, Partner, Risk Practice, Cambridge. Marcus’ area of expertise is risk management, in which he primarily focuses on developing next-generation risk management approaches, culture assessment, safety and risk governance and assurance, risk analysis, and executive leadership training, with deep industry experience in travel & transportation.
  • Dr. Engin Beken, Partner, Operations Management Practice, Frankfurt & Vienna. Engin is a key expert in strategic performance improvement and digitalization. He is a strong contributor to ADL’s global operations management practice and works with our clients globally, especially in asset-heavy industries.
  • Florence Carlot, Partner, Energy & Utilities Practice, Brussels. Florence focuses on strategy and organization in the energy & utilities industry. She has been working within the European energy and utilities sector for over 15 years, enabling large operational and strategic change initiatives across the energy value chain.
  • Julien Duvaud-Schelnast, Partner, Telecommunications, Information Technology, Media & Electronics (TIME) Practice, Paris & Stockholm. Operating in both France and Sweden, Julien is an expert on trending topics within the TIME practice, including infrastructure, private networks and sustainability.
  • Dr. Michael Eiden, Partner, Technology & Innovation Practice, London. Michael is the Global Head of Artificial Intelligence and Machine Learning at ADL. He is an industry expert with more than 20 years of hands-on experience in designing, developing and commercializing AI solutions in different industries.
  • Ben Enejo, Partner, Healthcare & Life Sciences Practice, Boston. Ben is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration; R&D transformation, including advanced technology application, increasing success for rare-disease drug development and launch; patient and drug safety; and quality and compliance excellence.
  • Mitsuhiro Henry Umebayashi, Partner, Strategy & Organization Practice, Singapore. Henry leads the S&O practice in South-East Asia and supports clients from multiple industries, such as consumer goods, energy & utilities, infrastructure and healthcare. His main focus is supporting clients with business transformation and growth acceleration arising from management challenges such as sustainability, globalization and digitalization.
  • Arjun Vir Singh, Partner, Financial Services Practice, Dubai. Arjun joined ADL in 2020 as the Head of Financial Services for the Middle East region. Actively engaged with fintech, payments, and digital banking, as well as the wider start-up ecosystem across the Middle East region and beyond, Arjun has deep sectorial knowledge. He has launched and managed a payments and fintech business for a large conglomerate across multiple markets in the Middle East and SEA region.

Ignacio Garcia Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I would like to congratulate our nine new Partners, who have worked hard and smart to become true entrepreneurs. Each promotion is richly deserved, and we are extremely grateful for the role they have played in the firm. At ADL we place tremendous value on our people. These nine colleagues have shown they are ready for the next step of their careers, and we are truly excited as they enter into their era of partnership.”

About Arthur D. Little

Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.

Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.

For further information, please visit www.adlittle.com or www.adl.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye